R&D News | pharmaphorum

News

Prospects for AstraZeneca and Ionis' Wainua have been severely dented by a failed trial in ATTR cardiomyopathy, weighing on the shares of both firms.

News

Many AIs used in drug discovery are provided by big tech companies at a cost, but a small US and China-based techbio is taking a different tack.

News

AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.

News

Fresh from a record-breaking IPO, Kailera revealed keenly anticipated trial results for its oral weight-loss drug, to a mixed reaction.

News

Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO.

News

Island Pharma has been granted the approvals needed to allow compassionate use of its antiviral galidesivir in the Bundibugyo Ebola outbreak.